1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Biofrontera Inc.

Biofrontera Inc.

BFRIW
Biofrontera Inc.US flagNASDAQ Capital Market
0.03
USD
- -
- -
355,472.00Market Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
26
19
24
29
34
37
42
43
Operating Margin (%)
-57
-44.21
-107.27
-78.05
-66.26
-46.11
-27.21
-24.83
Depreciation Expense
1
1
1
1
1
1
1
1
Net Income, GAAP
-11
-11
-38
-1
-20
-18
-11
-11
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-41.95
-58.29
-156.49
-2.23
-59.09
-47.58
-25.26
-25.66
Working Capital
12
15
33
22
5
9
6
2
LT Debt
38
- -
- -
1
1
4
6
7
Total Equity
-30
6
11
24
5
4
10
6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
8.67
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
1
LT Borrowings
4
5
5
LT Finance Leases
- -
1
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
14
18
13
Cash, Cash Equivalents & STI
3
6
6
Accounts Receivable, Net
3
7
4
Inventories
4
1
1
Total Current Liabilities
13
12
11
Payables & Accruals
9
8
6
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
50.82%
136.41%
Free Cash Flow
- -
20.2%
29.36%
Net Income, GAAP
- -
627.59%
-40.67%
Sales/Revenue/Turnover
- -
17.39%
11.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8
8
9
13
37
2025
9
9
7
17
42
2026
10
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Hermann Luebbert
Full Time Employees
92
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
120 Presidential Way Woburn DE United States of America 01801
IPO Date
Oct 29, 2021
CIK
0001858685
Website
biofrontera-us.com
Similar Companies
Chongqing Taiji Industry(Group) Co.,Ltd (600129.SS)
Benchmark Holdings plc (BMK.L)
NutraLife BioSciences, Inc. (NLBS)
Curaleaf Holdings, Inc. (CURA.TO)
Orexo AB (publ) (ORX.ST)
Cumberland Pharmaceuticals Inc. (CPIX)
Business
Biofrontera Inc. (Nasdaq: BFRI, BFRIW) is a U.S.-based biopharmaceutical company that commercializes pharmaceutical products for the treatment of dermatological conditions, with a focus on photodynamic therapy (PDT) and topical antibiotics; its core offerings include Ameluz (aminolevulinic acid hydrochloride gel, 10%), used in combination with the RhodoLED lamp series for the lesion-directed and field-directed treatment of mild-to-moderate actinic keratosis on the face and scalp, as well as Xepi (ozenoxacin cream, 1%), a topical non-fluorinated quinolone for the treatment of impetigo. The company, founded in 2015 and headquartered in Woburn, Massachusetts, operates primarily in the United States, targeting dermatologists and healthcare providers for patients with pre-cancerous skin lesions and bacterial skin infections. In 2025, Biofrontera completed a major restructuring of its relationship with former parent Biofrontera AG, acquiring full U.S. rights, New Drug Application, intellectual property, and patents for Ameluz and RhodoLED, supported by $11 million in financing that reduces royalty payments to 12-15% of U.S. net sales from prior levels of 25-35%; it also divested Xepi, received FDA Orange Book listing for a propylene glycol-free Ameluz formulation with patent protection to 2043, completed patient enrollment in Phase 3 trials for Ameluz-PDT on actinic keratoses of the extremities, neck, and trunk, and achieved key milestones in Phase 3 studies for superficial basal cell carcinoma and Phase 2b for acne vulgaris.

Company News

APIChat

  • globenewswire.com

    Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026